Skip to main content
SpringerLink
Log in

Novel Agents in Primary Central Nervous System Lymphoma

  • Chapter
  • First Online:
Novel Therapeutics for Rare Lymphomas

  • 490 Accesses

Abstract

Primary central nervous system lymphoma (PCNSL) is a rare and aggressive subtype of extranodal lymphoma. Although the addition of high-dose methotrexate-based therapies has improved patient outcomes in the first-line setting, the prognosis of relapsed and refractory disease is poor. PCNSL has a unique pathophysiology and gene expression profile, making it more amenable to novel targeted and immunotherapeutic agents. Therapies such as ibrutinib, nivolumab, and lenalidomide have shown promise in PCNSL. Future directions will include larger studies with these agents, as well as combination studies with novel agents and conventional chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 16.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hoffman SPJ, McCarthy BJ. Temporal trends in incidence of primary brain tumors in the United States, 1985–1999. Neuro-Oncology. 2006;8(1):27–37.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Villano JLKM, Shaikh H, Dolecek TA, McCarthy BJ. Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer. 2011;105(9):1414–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Bataille BDV, Menet E, et al. Primary intracerebral malignant lymphoma: report of 248 cases. Neurosurgery. 2000;92(2):261–6.

    Article  CAS  Google Scholar 

  4. Chan CC, Rubenstein J, Coupland SE, Davis JL, et al. Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium. Oncologist. 2011;16(11):1589–99.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Batchelor T, Carson K, O’Neill A, Grossman SA, et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol. 2003;21(6):1044–9.

    Article  CAS  PubMed  Google Scholar 

  6. Jahnke K, Korfel A, Martus P, et al. High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma. Ann Oncol. 2005;16(3):445–9.

    Article  CAS  PubMed  Google Scholar 

  7. Taylor JW, Flanagan E, O’Neill BP, Siegal T, et al. Primary leptomeningeal lymphoma: International Primary CNS Lymphoma Collaborative Group report. Neurology. 2013;81(19):1690–6.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Network NCC. Central nervous system cancers 2018. 2018. Available from: https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf.

  9. Abrey LE, Batchelor T, Ferreri AJ, International Primary CNS Lymphoma Collaborative Group, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23(22):5034–43.

    Article  PubMed  Google Scholar 

  10. Bühring U, Herrlinger U, Krings T, Thiex R, et al. MRI features of primary central nervous system lymphomas at presentation. Neurology. 2001;57(3):393–6.

    Article  PubMed  Google Scholar 

  11. Rubenstein JL. Biology of CNS lymphoma and the potential of novel agents. Hematol Am Soc Hematol Educ Program. 2017;1:556–64.

    Article  Google Scholar 

  12. Tabouret E, Houillier C, Martin-Duverneuil N, et al. Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial. Neuro-Oncology. 2017;19(3):422–9.

    CAS  PubMed  Google Scholar 

  13. Haldorsen IS, Espeland A, Larsson EM. Central nervous system lymphoma: characteristic findings on traditional and advanced imaging. Am J Neuroradiol. 2010;32(6):984–92.

    Article  PubMed  Google Scholar 

  14. O’Neill BP, Dinapoli R, Kurtin PJ, et al. Occult systemic non-Hodgkin’s lymphoma in patients initially diagnosed as primary central nervous system lymphoma: how much staging is enough? J Neuro-Oncol. 1995;25(1):67–71.

    Article  Google Scholar 

  15. Miller DC, Hochberg FH, Harris NL, Gruber ML, Louis DN, Cohen H. Pathology with clinical correlations of primary central nervous system non-Hodgkin’s lymphoma. The Massachusetts General Hospital experience 1958–1989. Cancer. 1994;74(4):1383–97.

    Article  CAS  PubMed  Google Scholar 

  16. Gijtenbeek JM, Rosenblum MK, DeAngelis LM. Primary central nervous system T-cell lymphoma. Neurology. 2001;57(4):716–8.

    Article  CAS  PubMed  Google Scholar 

  17. de Castro AF, Junior AS, de Lins e Horta H, Neuenschwander LC, Fonseca RP, Lima SS, et al. Primary intracerebral Hodgkin lymphoma. Br J Haematol. 2007;138(5):562.

    Article  PubMed  Google Scholar 

  18. Jahnke K, Korfel A, O’Neill BP, Blay JY, Abrey LE, Martus P, et al. International study on low-grade primary central nervous system lymphoma. Ann Neurol. 2006;59(5):755–62.

    Article  PubMed  Google Scholar 

  19. Ferreri AJ, Blay J, Reni M, Pasini F, et al. Prognostic scoring system for primary CNS lymphomas: The International Extranodal Lymphoma Study Group experience. J Clin Oncol. 2003;21(2):266–72.

    Article  PubMed  Google Scholar 

  20. Shibamoto Y, Ogino H, Hasegawa M, Suzuki K, et al. Results of radiation monotherapy for primary central nervous system lymphoma in the 1990s. Int J Radiat Oncol Biol Phys. 2005;62(3):809–13.

    Article  PubMed  Google Scholar 

  21. Nelson DF, Martz K, Bonner H, Nelson JS, et al. Non-Hodgkin’s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys. 1992;23(1):9–17.

    Article  CAS  PubMed  Google Scholar 

  22. Shibamoto Y, Hayabuchi N, Hiratsuka J, et al. Is whole-brain irradiation necessary for primary central nervous system lymphoma? Patterns of recurrence after partial-brain irradiation. Cancer. 2003;97(1):128–33.

    Article  PubMed  Google Scholar 

  23. Grommes C, DeAngelis L. Primary CNS lymphoma. J Clin Oncol. 2017;35(21):2410–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Schultz C, Scott C, Sherman W, et al. Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88-06. J Clin Oncol. 1996;14(2):556–64.

    Article  CAS  PubMed  Google Scholar 

  25. Mead GM, Bleehen N, Gregor A, Bullimore J, et al. A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy. Cancer. 2000;89(6):1359–70.

    Article  CAS  PubMed  Google Scholar 

  26. Surapaneni UR, Cortes J, Thomas D, O’Brien S, et al. Central nervous system relapse in adults with acute lymphoblastic leukemia. Cancer. 2002;94(3):773–9.

    Article  PubMed  Google Scholar 

  27. Kantarjian HM, O’Brien S, Smith TL, Cortes J, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 2000;18(3):547–61.

    Article  CAS  PubMed  Google Scholar 

  28. Sancho JM, Ribera J, Oriol A, Hernandez-Rivas JM, et al. Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis. Cancer. 2006;106(12):2540–6.

    Article  CAS  PubMed  Google Scholar 

  29. Lippens RJ, Winograd B. Methotrexate concentration levels in the cerebrospinal fluid during high-dose methotrexate infusions: an unreliable prediction. Pediatr Hematol Oncol. 1988;5(2):115–24.

    Article  CAS  PubMed  Google Scholar 

  30. DeAngelis LM, Yahalom J, Thaler HT, Kher U, et al. Combined modality therapy for primary CNS lymphoma. J Clin Oncol. 1992;10(4):635–43.

    Article  CAS  PubMed  Google Scholar 

  31. O’Brien P, Roos D, Pratt G, Liew K, et al. Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol. 2000;18(3):519–26.

    Article  PubMed  Google Scholar 

  32. Glass J, Gruber M, Cher L, Hochberg FH. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg. 1994;81(2):188–95.

    Article  CAS  PubMed  Google Scholar 

  33. Ferreri AJ, Reni M, Foppoli M, Martelli M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet Oncol. 2009;374(9700):1512–20.

    Article  CAS  Google Scholar 

  34. Rubenstein JL, Hsi E, Johnson JL, Jung SH, et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol. 2013;31(25):3061–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Glass J, Won M, Schultz CJ, Brat D, et al. Phase I and II study of induction chemotherapy with methotrexate, rituximab, and temozolomide, followed by whole-brain radiotherapy and postirradiation temozolomide for primary CNS lymphoma: NRG oncology RTOG 0227. J Clin Oncol. 2016;34(14):1620–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Morris PG, Correa D, Yahalom J, Raizer JJ, et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol. 2013;31(31):3971–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016;3(5):217–27.

    Article  Google Scholar 

  38. Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, et al. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematol. 2017;4(11):510–23.

    Article  Google Scholar 

  39. Omuro A, Correa D, DeAngelis LM, Moskowitz CH, et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood. 2015;125(9):1403–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Ferreri AJ, Illerhaus G. The role of autologous stem cell transplantation in primary central nervous system lymphoma. Blood. 2016;127(13):1642–9.

    Article  CAS  PubMed  Google Scholar 

  41. Wiebe VJ, Smith B, DeGregorio MW, Rappeport JM. Pharmacology of agents used in bone marrow transplant conditioning regimens. Crit Rev Oncol Hematol. 1992;13(3):241–70.

    Article  CAS  PubMed  Google Scholar 

  42. Cote GM, Hochberg E, Muzikansky A, Hochberg FH, et al. Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2012;18(1):76–83.

    Article  CAS  PubMed  Google Scholar 

  43. Cheng T, Forsyth P, Chaudhry A, Morris D, et al. High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone Marrow Transplant. 2003;31(8):679–85.

    Article  CAS  PubMed  Google Scholar 

  44. Illerhaus G, Müller F, Feuerhake F, Schäfer AO, et al. High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica. 2008;93(1):147–8.

    Article  CAS  PubMed  Google Scholar 

  45. Bojic M, Berghoff A, Troch M, Agis H, et al. Haematopoietic stem cell transplantation for treatment of primary CNS lymphoma: single-centre experience and literature review. Eur J Haematol. 2015;95(1):75–82.

    Article  PubMed  Google Scholar 

  46. Network NCC. Central nervous system cancers: National Comprehensive Cancer Network. 2018. Available from: https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf.

  47. Enting RH, Demopoulos A, DeAngelis LM, Abrey LE. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology. 2004;63(5):901–3.

    Article  CAS  PubMed  Google Scholar 

  48. Chamberlain MC. High-dose cytarabine salvage therapy for recurrent primary CNS lymphoma. J Neuro-Oncol. 2016;126(3):545–50.

    Article  CAS  Google Scholar 

  49. Fischer L, Thiel E, Klasen HA, Birkmann J, Jahnke K, Martus P, et al. Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann Oncol. 2006;17(7):1141–5.

    Article  CAS  PubMed  Google Scholar 

  50. Raizer JJ, Rademaker A, Evens AM, Rice L, Schwartz M, Chandler JP, et al. Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma. Cancer. 2012;118(15):3743–8.

    Article  CAS  PubMed  Google Scholar 

  51. Camilleri-Broët S, Crinière E, Broët P, Delwail V, et al. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood. 2006;107(1):190–6.

    Article  PubMed  CAS  Google Scholar 

  52. Davis RE, Brown K, Siebenlist U, Staudt LM. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med. 2001;194(12):1861–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Vlahopoulos SA. Aberrant control of NF-κB in cancer permits transcriptional and phenotypic plasticity, to curtail dependence on host tissue: molecular mode. Cancer Biol Med. 2017;14(3):254–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Chapuy B, Roemer M, Stewart C, et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 2016;127(7):869–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Davis RE, Ngo V, Lenz G, Tolar P, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463(7277):88–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Wilson WH, Young R, Schmitz R, Yang Y, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21(8):922–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Bernard S, Goldwirt L, Amorim S, Brice P, et al. Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse. Blood. 2015;126(14):1695–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Grommes C, Pastore A, Palaskas N, Tang SS, et al. Ibrutinib unmasks critical role of Bruton tyrosine kinase in primary CNS lymphoma. Cancer Discov. 2017;7(9):1018–29.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Choquet S, Houillier C, Bijou F, Houot R, et al. Ibrutinib monotherapy in relapse or refractory Primary CNS Lymphoma (PCNSL) and Primary Vitreo-Retinal Lymphoma (PVRL). Result of the Interim Analysis of the iLOC Phase II Study from the Lysa and the French LOC Network. Blood. 2016;128(22):784.

    Article  Google Scholar 

  60. Lionakis MS, Dunleavy K, Roschewski M, Widemann BC, et al. Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma. Cancer Cell. 2017;31(6):833–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Grommes C, Younes A. Ibrutinib in PCNSL: the curious cases of clinical responses and aspergillosis. Cancer Cell. 2017;31(6):731–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Grommes C, Stone J, Nolan C, Tsyvkin E, Wolfe J, Mellinghoff IK, et al. Phase 1B of ibrutinib and high-dose methotrexate for recurrent/refractory CNS lymphoma. J Clin Oncol. 2017;35(15_suppl):7533.

    Article  Google Scholar 

  63. Andorsky DJ, Yamada R, Said J, Pinkus GS, et al. Programmed death ligand 1 is expressed by non-Hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin Cancer Res. 2011;17(13):4232–44.

    Article  CAS  PubMed  Google Scholar 

  64. Lesokhin AM, Ansell S, Armand P, Scott EC, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol. 2016;34(23):2698–704.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Rubenstein JL, Fridlyand J, Shen A, Aldape K, et al. Gene expression and angiotropism in primary CNS lymphoma. Blood. 2006;107(9):3716–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Nayak L, Iwamoto F, LaCasce A, Mukundan S, et al. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. Blood. 2017;129(23):3071–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, Pileri SA, et al. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer. 2011;117(22):5058–66.

    Article  CAS  PubMed  Google Scholar 

  68. Yang Y, Shaffer AI, Emre NC, Ceribelli M, et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell. 2012;21(6):723–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Wu L, Adams M, Carter T, Chen R, et al. Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res. 2008;14(14):4650–7.

    Article  CAS  PubMed  Google Scholar 

  70. Wang M, Fowler N, Wagner-Bartak N, Feng L, et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia. 2013;27(9):1902–9.

    Article  CAS  PubMed  Google Scholar 

  71. Zinzani PL, Pellegrini C, Gandolfi L, Stefoni V, et al. Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. Clin Lymphoma Myeloma Leuk. 2011;11(6):462–6.

    Article  CAS  PubMed  Google Scholar 

  72. Rubenstein JL, Fraser E, Formaker P, Lee JCC, et al. Phase I investigation of lenalidomide plus rituximab and outcomes of lenalidomide maintenance in recurrent CNS lymphoma. J Clin Oncol. 2016;34(15 Suppl):7502.

    Article  Google Scholar 

  73. Ghesquieres H, Houillier C, Chinot O, Choquet S, et al. Rituximab-Lenalidomide (REVRI) in relapse or refractory Primary Central Nervous System (PCNSL) or Vitreo Retinal Lymphoma (PVRL): results of a “Proof of Concept” phase II study of the French LOC Network. Blood. 2016;128(22):785.

    Article  Google Scholar 

  74. Tun HW, Johnston P, Grommes C, Reeder CB, et al. Phase I clinical trial on pomalidomide and dexamethasone in treating patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) or primary vitreoretinal lymphoma (PVRL). J Clin Oncol. 2017;35(15 Suppl):7516.

    Article  Google Scholar 

  75. Kuhn JG, Chang S, Wen PY, et al. Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma. Clin Cancer Res. 2007;13(24):7401–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Korfel A, Schlegel U, Herrlinger U, Dreyling M, et al. Phase II trial of temsirolimus for relapsed/refractory primary CNS lymphoma. J Clin Oncol. 2016;34(15):1757–63.

    Article  CAS  PubMed  Google Scholar 

  77. Schuster SJ, Svoboda J, Chong EA, Nasta SD, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017;377(26):2545–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Neelapu SS, Locke F, Bartlett NL, Lekakis LJ, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Kochenderfer JN, Dudley M, Kassim SH, Somerville RP, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33(6):540–9.

    Article  CAS  PubMed  Google Scholar 

  80. Grupp SA, Kalos M, Barrett D, Aplenc R, et al. Chimeric antigen receptor–modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509–18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Abramson JS, McGree B, Noyes S, Plummer S, et al. Anti-CD19 CAR T cells in CNS diffuse large-B-cell lymphoma. N Engl J Med. 2017;377(8):783–4.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Hematology and Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

    Raghuveer Ranganathan & Natalie Sophia Grover

Authors
  1. Raghuveer Ranganathan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Natalie Sophia Grover
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Natalie Sophia Grover .

Editor information

Editors and Affiliations

  1. Department of Medicine, Division of Hematology and Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

    Christopher Dittus

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Ranganathan, R., Grover, N.S. (2020). Novel Agents in Primary Central Nervous System Lymphoma. In: Dittus, C. (eds) Novel Therapeutics for Rare Lymphomas. Springer, Cham. https://doi.org/10.1007/978-3-030-25610-4_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-25610-4_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-25609-8

  • Online ISBN: 978-3-030-25610-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation